Anormalidades significativas en pruebas de función hepática secundariasa nutrición parenteral y su asociación con mortalidad

González Santos, A; Gutiérrez Hermosillo, H; Díaz de León González, E; Tamez Pérez, HE.
Nutr. hosp ; 26(1): 243-243, ene.-feb. 2011. ilus
Artículo en Español | IBECS (España) | ID: ibc-94149

Documentos relacionados

  1. Factors and a model to predict three-month mortality in patients with acute fatty liver of pregnancy from two medical centers.
  2. Fatty liver haemorrhagic syndrome occurrence in laying hens: impact of production system.
  3. Acute Fatty Liver of Pregnancy.
  4. A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.
  5. Treatment-related problems in neonates receiving parenteral nutrition: risk factors and implications for practice.
  6. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
  7. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
  8. Prevalence and mortality prognosis of steatotic liver disease phenotypes.
  9. Offering Guidance and Learning to Prescribers to Initiate Parenteral Nutrition using a Validated Electronic Decision TREE (OLIVE TREE).
  10. Fatty liver, cardiometabolic disease and mortality.